| Identification | Back Directory | [Name]
DMAPT | [CAS]
870677-05-7 | [Synonyms]
DMAPT
Dimethylamino Parthenolide
UJNSFDHVIBGEJZ-KVUCBBCISA-N
NF-κB,Inhibitor,Nuclear factor-κB,inhibit,DMAPT,Nuclear factor-kappaB
(1S,2R,4R,7~{Z},11S,12S)-12-[(dimethylamino)methyl]-4,8-dimethyl-3,14-dioxatricyclo[9.3.0.0^{2,4}]tetradec-7-en-13-one
Oxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, 8-[(dimethylamino)methyl]-2,3,6,7,7a,8,10a,10b-octahydro-1a,5-dimethyl-, (1aR,4E,7aS,8S,10aS,10bR)- | [Molecular Formula]
C17H27NO3 | [MDL Number]
MFCD32062837 | [MOL File]
870677-05-7.mol | [Molecular Weight]
293.4 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO, Ethyl acetate, or Ethanol. | [form ]
solid | [color ]
White | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO, ethanol, or ethyl acetate may be stored at -20° for up to 1 month. |
| Hazard Information | Back Directory | [Description]
DMAPT (870677-05-7) is a water soluble analog of the natural plant product parthenolide (Cat.# 10-2096) which suppresses in vivo tumor growth of two tobacco-associated neoplasms, lung and bladder cancer. It inhibits NFκB and stimulates the formation of reactive oxygen species which induced the activation of JNK.1 In non-small cell lung cancers DMAPT inhibits NFκB and DNA double-strand break repair.2 | [Uses]
DMAPT is a parthenolide derivative that functions as an antileukemic and cytotoxic agents. | [in vivo]
Treatment with DMAPT (100 mg/kg, Oral gavage daily for 7 days) increases sensitivity of PC-3 tumor xenografts to X-rays[2].
DMAPT (100 mg/kg, Oral gavage thrice weekly from 42 to 300 days since birth) treatment slows normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%[3].
DMAPT further reduces the metastatic area below that of the water vehicle treatment group in lung tissues (0.10% ± 0.15 SD, 92% reduction, p = 0.0028) in TRAMP mice[3].
| [References]
1) Shanmugam?et al. (2011),?A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NFκB and generating reactive oxygen species; Int. J. Cancer,?128?2481
2) Estrabrook?et al. (2011),?Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays; Free Radic. Biol. Med.,?51?2249 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Carbosynth
|
| Tel: |
+86 512 6260 5585 |
| Website: |
www.carbosynth.com |
|